Atacand
Product Images NDC 68151-4146

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Atacand (NDC 68151-4146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Chemical structure diagram showing the molecular structure of the active ingredient in ATACAND, highlighting the site of ester hydrolysis.*

FDA Label Image

Figure 1 Graph (Image 02)

A forest plot illustrating hazard ratios with 95% confidence intervals for various patient subgroups in a study comparing ATACAND versus placebo. Subgroups include age, sex, race, NYHA class, LVEF levels, and medical history factors such as diabetes, hypertension, and prior myocardial infarction, among others. The plot shows relative treatment effects, with markers indicating hazard ratios and confidence intervals for each subgroup and an overall patient summary at the bottom.*

FDA Label Image

Label Image (Lbl681514146)

ATACAND 8 MG tablet packaging label showing the active ingredient candesartan cilexetil. The label includes manufacturer AstraZeneca, lot number BT0076, expiration date 08/14, product NDC 68151-4146, and a barcode. The product is marked Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.